Teva Canada Partners with Novartis to Commercialize Multiple Sclerosis Treatment Mayzent
核心洞察
Teva Canada (搜索) has entered into a strategic commercialization and supply agreement with Novartis Canada (搜索) to assume exclusive responsibility for promoting and distributing Mayzent (siponimod) in Canada.
The partnership leverages Teva's established central nervous system expertise and national commercial infrastructure to ensure continued access to this oral treatment for secondary progressive multiple sclerosis (搜索) patients.
Mayzent is indicated for treating patients with secondary progressive multiple sclerosis (搜索) with active disease to delay the progression of physical disability.
Teva Canada (搜索) Limited has announced a strategic partnership with Novartis Pharmaceuticals Canada Inc. to relaunch and commercialize Mayzent (siponimod), an oral treatment for secondary progressive multiple sclerosis (搜索) (SPMS) with active disease. Under the new agreement, Teva Canada will assume exclusive responsibility for the promotion, distribution, and commercialization of Mayzent in Canada.
Strategic Partnership Details
The collaboration is designed to leverage Teva's established central nervous system (CNS) expertise and national commercial infrastructure to ensure continued access to Mayzent for Canadian patients and healthcare professionals. The agreement aims to maximize the reach and impact of the therapy by building on Teva's established relationships with neurologists and MS specialists across the country.
"This is about more than a product - it's about people," said Fabien Paquette, General Manager of Teva Canada (搜索). "Through this partnership, we are reaffirming our dedication to the MS community and to patient-centred care. Teva Canada is proud to lead with purpose, ensuring access and support for those who need it most."
Dimitri Gitas, Country President of Novartis Canada (搜索), emphasized the shared commitment to MS patients: "This agreement reflects our shared responsibility to support people living with MS. Through this partnership, we're strengthening support for Canadians living with multiple sclerosis (搜索) and advancing better health outcomes nationwide."
Treatment Indication and Mechanism
Mayzent is indicated in Canada for the treatment of patients with secondary progressive multiple sclerosis (搜索) with active disease, as evidenced by relapses or imaging features characteristic of multiple sclerosis (搜索) inflammatory activity. The oral therapy is designed to delay the progression of physical disability in this patient population.
Company Background
Teva Canada (搜索), a subsidiary of Teva Pharmaceutical Industries (搜索) Ltd., operates as one of the world's largest suppliers of generic, biosimilar, and innovative medicines. The company maintains facilities in Markham, Stouffville, Toronto, and Montréal, employing over 850 people and manufacturing 70% of the medicines it sells in Canada locally. This domestic manufacturing capacity reinforces the company's commitment to accessibility and supports the Canadian economy.